OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
KMT2C inactivation leads to PTEN downregulation and tolerance to DNA damage during cell cycle progression	450
MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways	232
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies	171
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson	159
High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer	152
Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning	151
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates	151
Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment	147
Barriers and opportunities in pancreatic cancer immunotherapy	133
Author Correction: An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	115
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1	106
AI-enabled single-cell dissection of the palmitoylation landscape identifies a multicellular prognostic program in gastric cancer	102
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood	96
Sub-regional radiomics combining multichannel 2-dimensional or 3-dimensional deep learning for predicting neoadjuvant chemo-immunotherapy response in esophageal squamous cell carcinoma: a multicenter	94
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	83
Mucin-1: a promising pan-cancer therapeutic target	78
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants	77
Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo axis	76
Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study	76
Artificial intelligence-driven prediction of lymph node metastasis in T1 esophageal squamous cell carcinoma using whole slide images	73
Development and testing of a polygenic risk score for breast cancer aggressiveness	72
The dynamic immune behavior of primary and metastatic ovarian carcinoma	68
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	68
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials	67
An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	67

Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)	65
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	64
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	64
Patient-level proteomic network prediction by explainable artificial intelligence	63
Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers	59
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes	59
Spatial transcriptomics reveals molecular heterogeneity and subtype-specific therapeutic targets in small cell lung cancer	58
Single nuclei and spatial profiling of sacrococcygeal teratomas reveals cellular composition and X inactivation heterogeneity	58
Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers	58
Interferon signaling and ferroptosis in tumor immunology and therapy	57
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	56
Collagen disorder architecture features are associated with clinical, molecular, genetic factors and survival outcomes in colon cancer	55
Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis	54
m6A reader IGF2BP2-stabilized lncRNA LHX1-DT inhibits renal cell carcinoma (RCC) cell proliferation and invasion by sponging miR-590-5p	53
Targeting Nrf2/PHKG2 axis to enhance radiosensitivity in NSCLC	52
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma	52
Discovery of prognostic lncRNAs in colorectal cancer using spatial transcriptomics	50
Stage-dependent spatial distribution and prognostic value of CD8+ tissue-resident memory T cells in NSCLC	49
Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients	48
Erigoster B targeting DECR1 induces ferroptosis of breast cancer cells via promoting phosphatidylcholine/arachidonic acid metabolism	48
Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology	47
AI-driven body composition atlas reveals its association with NSCLC immunotherapy outcome and molecular background: a multicenter study	47